ir.cnspharma.comInvestor Relations :: CNS Pharmaceuticals, Inc. (CNSP)
ir.cnspharma.com Profile
Ir.cnspharma.com is a subdomain of cnspharma.com, which was created on 2016-05-13,making it 8 years ago.
Discover ir.cnspharma.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.cnspharma.com Information
| HomePage size: 194.164 KB |
| Page Load Time: 0.14689 Seconds |
| Website IP Address: 52.192.255.39 |
ir.cnspharma.com Similar Website
| Masonite International Corp. - Investor Relations - Investor Relations |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Universal Technical Institute's Investor Relations - UTI Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Meridian Bank Investor Relations - Meridian Bank Investor Relations |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations |
| Home - Harvard CNS - Harvard CNS |
| Walmart Investor Relations - Investor Relations |
| CNS Job Market – jobs in psychiatry, neurology, and primary care and medical fields with a CNS focus |
ir.cnspharma.com PopUrls
| Investor Relations :: CNS Pharmaceuticals, Inc. (CNSP) https://ir.cnspharma.com/ |
| Corporate Governance https://ir.cnspharma.com/corporate-governance |
| SEC Filings https://ir.cnspharma.com/sec-filings |
| Company Information https://ir.cnspharma.com/company-information |
| Financial Information https://ir.cnspharma.com/financial-information |
| News & Events https://ir.cnspharma.com/news-events |
| Analyst Coverage https://ir.cnspharma.com/analyst-coverage |
| Charts https://ir.cnspharma.com/stock-data/charts |
| Quote https://ir.cnspharma.com/stock-data/quote |
| FAQ https://ir.cnspharma.com/company-information/faq |
ir.cnspharma.com Httpheader
| Date: Sun, 12 May 2024 15:37:28 GMT |
| Server: Apache |
| Expires: Thu, 19 Nov 1981 08:52:00 GMT |
| Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 |
| Pragma: no-cache |
| Set-Cookie: major_announcement=deleted; expires=Thu, 01-Jan-1970 00:00:01 GMT; Max-Age=0 |
| Vary: Accept-Encoding |
| Transfer-Encoding: chunked |
| Content-Type: text/html; charset=UTF-8 |
ir.cnspharma.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-Type"/ |
| content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport"/ |
| content="https://ir.cnspharma.com" property="og:url"/ |
| content="CNS Pharmaceuticals, Inc." property="og:site_name"/ |
| content="Investor Relations" property="og:title"/ |
| content="website" property="og:type"/ |
| content="https://d1io3yog0oux5.cloudfront.net/_37b814d07a5e45a4156c3ccdffd40e44/cnspharmaceuticals/db/364/2360/social_image_resized.jpg" property="og:image"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress." name="generator" |
| content="wordpress-plugin" name="onesignal" |
| content="#ffffff" name="theme-color"/ |
ir.cnspharma.com Ip Information
| Ip Country: Japan |
| City Name: Tokyo |
| Latitude: 35.6893 |
| Longitude: 139.6899 |
ir.cnspharma.com Html To Plain Text
Brain Glioblastoma Anthracyclines Blood Brain Barrier Technology Berubicin Pipeline Team Management BoardContact Investors Sign Up Investor Relations Investors Investors Overview News & Events Overview Press Releases IR Calendar Email Alerts Company Info Overview Management Team Presentations Contacts FAQ Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow Analyst Coverage Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Latest News CNS Pharmaceuticals to Present at the LSX World Congress 2024 Apr 23, 2024 View Press Release CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity Apr 22, 2024 CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements Apr 1, 2024 View All News Latest Presentation Investor Presentation View Presentation Shareholder Letter Shareholder Letter January 27, 2022 View Letter Recent Event Apr 30, 2024 • 3:00 pm EDT Annual Meeting of Stockholders View Event View All Latest Financial Results FY 2023 Fiscal Year Ended Dec 31, 2023 Earnings Release PDF HTML 10-K Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Dec 31, 2023 Report Links Annual Report Document Links View 10-K Sign Up For Email Alerts Receive updates straight into your inbox Sign up today Company Overview CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM) an aggressive and incurable form of brain cancer. Additionally the Company is advancing the development of its WP1244 drug technology which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers pancreatic ovarian and lymphomas. View Management Team View Board of Directors Investor Contact Information Company CNS Pharmaceuticals, Inc. 2100 West Loop South Suite 900 Houston, TX 77027 Investor Relations JTC Team, LLC Jenene Thomas T: 833-475-8247 cnsp@jtcir.com IR@cnspharma.com Transfer Agent Continental Stock Transfer & Trust Company 1 State Street 30th Floor New York, NY 10004 T: 800-509-5586 cstmail@continentalstock.com Email Alerts Tear Sheet Contacts RSS News Feed © 2024 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma Market Data copyright © 2024 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use . Brain Glioblastoma Anthracyclines Blood Brain Barrier Technology Berubicin Pipeline Team Management BoardContact Investors Sign...
ir.cnspharma.com Whois
Domain Name: CNSPHARMA.COM Registry Domain ID: 2027854004_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-05-13T18:49:18Z Creation Date: 2016-05-13T00:07:55Z Registry Expiry Date: 2025-05-13T00:07:55Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: ANNA.NS.CLOUDFLARE.COM Name Server: SAGE.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T13:34:32Z <<<